- PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
- Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubinski J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PDP, Siesling S, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK.
- Breast Cancer Res. 2022 Oct 21;24(1):69. doi: 10.1186/s13058-022-01567-3.
- PMID: 36271417
- PubMed abstract
- Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance.
- Corvaja C, Taurelli Salimbeni B, Nicolò E, Puglisi F, Curigliano G.
- Expert Opin Pharmacother. 2022 Oct 21. doi: 10.1080/14656566.2022.2139176. Epub ahead of print.
- PMID: 36268855
- PubMed abstract
- Commentary
- Free Full Text
- APC germline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?
- Vibert R, Le Gall J, Buecher B, Mouret-Fourme E, Bataillon G, Becette V, Trabelsi-Grati O, Moncoutier V, Dehainault C, Carriere J, Schwartz M, Suybeng V, Bieche I, Colas C, Vincent-Salomon A, Stoppa-Lyonnet D, Golmard L.
- J Med Genet. 2022 Oct 21:jmedgenet-2022-108467. doi: 10.1136/jmg-2022-108467. Epub ahead of print.
- PMID: 36270768
- PubMed abstract
- Source abstract
- Case report
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
- O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, Swisher EM, Maloney L, Goble S, Lin KK, Kwan T, Ledermann JA, Coleman RL.
- Gynecol Oncol. 2022 Oct 20:S0090-8258(22)00575-3. doi: 10.1016/j.ygyno.2022.08.021. Epub ahead of print.
Identifier: NCT01968213: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3). (ClinicalTrials.gov . Accessed 2022 Oct 22.)
- Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
- Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, Parachoniak CA, McLaughlin-Drubin M, Erlich RL, Schrock AB, Frampton GM, Das Thakur M, Oxnard GR, Tukachinsky H.
- JCO Precis Oncol. 2022 Oct [20];6:e2200261. doi: 10.1200/PO.22.00261.
- PMID: 36265119
- PubMed abstract
- Source abstract
- Population genomic screening: Ethical considerations to guide age at implementation.
- Spencer SJ, Fullerton SM.
- Front Genet. 2022 Oct 4;13:899648. doi: 10.3389/fgene.2022.899648.
- PMID: 36267415
- PubMed abstract
- Review
- Free Full Text